Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
RESEARCH TOOLSreports
Holding YMAB?
Track your performance easily
Earnings Data
Report Date
Feb 20, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.02Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 22, 2019
|% Change Since: -60.45%
|Next Earnings Date:Nov 13, 2018
Earnings Call Sentiment|Neutral
While Y-mAbs demonstrated strategic growth through partnerships and clinical advancements, the company faced revenue declines and increased operating expenses. Despite progress in physician adoption and ex-U.S. market expansion, challenges in the U.S. market and overall financial performance were notable.Company Guidance
During the third quarter of 2024, Y-mAbs Therapeutics, Inc. reported total net revenue of $18.5 million, marking a 10% decline from the same period in 2023 due to decreased net product revenues both in the U.S. and internationally. Despite this, DANYELZA, their key product, saw a 5% increase in demand compared to the second quarter, attributed to physician adoption across new and existing accounts. The company opened three new U.S. DANYELZA accounts during the quarter. They continued their expansion efforts, including entering an exclusive agreement with Noble Pharma for DANYELZA's potential commercialization in Japan, with an upfront payment of $2 million and up to $31 million in milestone payments. The company's cash and cash equivalents stood at $68.1 million at the end of the quarter, and they reiterated their full-year revenue guidance to range between $87 million and $95 million, expecting results to come in the lower half of that range. Operating expenses were projected to remain between $115 million and $120 million for the year, with cash investment anticipated between $15 million and $20 million.Expansion and Partnership Initiatives
Y-mAbs received a patent extension for DANYELZA, expiring in 2034, and entered into an exclusive license agreement with Noble Pharma for DANYELZA development and commercialization in Japan, with an upfront payment of $2 million and potential milestones of up to $31 million.
Clinical Progress in SADA Programs
Phase I trials for GD2-SADA and CD38-SADA are progressing well, with no dose-limiting toxicities reported. The GD2-SADA trial expanded to include adult neuroblastoma patients, demonstrating proof of concept.
Increased Physician Adoption
DANYELZA saw a 5% increase in demand and added 3 new U.S. accounts in the third quarter, indicating growing physician adoption and patient access.
Ex-U.S. Market Expansion
DANYELZA sales were recorded in Turkey for the first time, and sales continued in Brazil and Mexico, indicating progress in ex-U.S. market penetration.
---
YMAB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
YMAB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 08, 2024 | $15.55 | $15.48 | -0.45% |
| Aug 12, 2024 | $11.21 | $9.95 | -11.24% |
| May 07, 2024 | $17.21 | $13.61 | -20.92% |
| Feb 29, 2024 | $16.70 | $18.69 | +11.92% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Y-Mabs Therapeutics (YMAB) report earnings?
Y-Mabs Therapeutics (YMAB) is schdueled to report earning on Feb 20, 2025, TBA Not Confirmed.
What is Y-Mabs Therapeutics (YMAB) earnings time?
Y-Mabs Therapeutics (YMAB) earnings time is at Feb 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is YMAB EPS forecast?
YMAB EPS forecast for the fiscal quarter 2024 (Q4) is -0.1.
---